CRISPR Therapeutics Reports $10.2M Revenue in Q2 2026, Net Loss Improves to $91.2M

CRISPR Therapeutics AG reported its financial results for the second quarter of 2026, revealing a total revenue of $10.2 million, a significant increase from $892,000 in the same period last year. The revenue primarily stemmed from collaboration agreements, with $10 million attributed to an upfront payment from a new license agreement. For the first half of 2026, total revenue reached $11.6 million, compared to $1.8 million in the first half of 2025. The company’s net loss for the second quarter was $91.2 million, a notable improvement from a loss of $208.5 million in the prior year, while the loss for the first half of 2026 was $214.1 million, down from $344.5 million in the same period of 2025.

Operating expenses for the second quarter of 2026 totaled $127.5 million, a decrease from $230.2 million in the same quarter of 2025. This reduction was driven by lower research and development costs, which fell to $67.2 million from $69.9 million year-over-year, and a significant drop in acquired in-process research and development expenses, which were not material in the latest quarter compared to $96.3 million in the previous year. General and administrative expenses also decreased to $17.6 million from $18.9 million. The company reported a collaboration expense of $40.3 million, down from $45.2 million, reflecting a more favorable cost-sharing arrangement with its partner Vertex Pharmaceuticals.

In terms of operational metrics, CRISPR Therapeutics ended the second quarter with total assets of $2.65 billion, up from $2.27 billion at the end of 2025. The company’s cash and cash equivalents decreased to $291.3 million from $347.6 million, while marketable securities increased to $2.07 billion from $1.63 billion. The total liabilities surged to $904.2 million, primarily due to the issuance of $600 million in convertible senior notes in March 2026, which contributed to a net cash inflow of $599.1 million from financing activities during the first half of the year.

Strategically, CRISPR Therapeutics has made significant advancements in its product pipeline, particularly with the approval of its CRISPR-based therapy, CASGEVY, which is now available for patients aged 2 years and older with sickle cell disease and transfusion-dependent beta-thalassemia. The company is also advancing its collaboration with Sirius Therapeutics, focusing on siRNA-based therapies, and has initiated several clinical trials for its in vivo gene editing programs. The company’s employee headcount has remained stable, supporting its ongoing research and development efforts.

Looking ahead, CRISPR Therapeutics anticipates continued investment in its research and development activities, with expectations to fund operations for at least the next 24 months using existing cash and marketable securities. The company acknowledges the need for additional capital to support long-term clinical development and commercialization efforts, and it plans to explore various financing opportunities as market conditions permit. The outlook remains cautiously optimistic, with a focus on advancing its innovative gene-editing technologies and expanding its therapeutic offerings.